Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials
- 12 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 23 (2), 1-10
- https://doi.org/10.1208/s12248-021-00556-2
Abstract
Pancreatic cancer is a highly malignant tumor and one of the primary causes of cancer-related death. Because pancreatic cancer is difficult to diagnose in the early course of the disease, most patients present with advanced lesions at the time of diagnosis, and only 20% of patients are eligible for surgery. Consequently, drug treatment has become extremely important. At present, the main treatment regimens for pancreatic cancer are gemcitabine and the FORFIRINOX and MPACT regimens. However, none of these regimens substantially improves the prognosis of patients with pancreatic cancer. Extensive efforts have been dedicated to the study of pancreatic cancer in recent years. With the development and clinical application of biological targeted drugs, the biological targeted treatment of tumors has been widely accepted. Therefore, this article used relevant clinical trial data to summarize the research progress of traditional chemotherapy drugs and biological targeted drugs for the treatment of pancreatic cancer.This publication has 100 references indexed in Scilit:
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized TrialJournal of Clinical Oncology, 2013
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancerBritish Journal of Cancer, 2012
- Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape MechanismsJournal of Immunology Research, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Journal of Clinical Oncology, 2010
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studiesBMC Cancer, 2010
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future VistasJapanese Journal of Clinical Oncology, 2008
- Pancreatic CancerAnnual review of pathology, 2008
- Disrupting insulin-like growth factor signaling as a potential cancer therapyMolecular Cancer Therapeutics, 2007